

# David J Bond

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6565318/publications.pdf>

Version: 2024-02-01

80  
papers

6,106  
citations

156536

32  
h-index

93651

72  
g-index

82  
all docs

82  
docs citations

82  
times ranked

6598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Causal pathways to social and occupational functioning in the first episode of schizophrenia: uncovering unmet treatment needs. <i>Psychological Medicine</i> , 2023, 53, 2041-2049.	2.7	11
2	Comparison of Demographic and Clinical Features of Bipolar Disorder in Persons of African and European Ancestry. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 367-372.	1.8	1
3	Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. <i>Frontiers in Psychiatry</i> , 2022, 13, 884217.	1.3	3
4	Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. <i>Journal of Affective Disorders</i> , 2022, 310, 150-155.	2.0	5
5	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. <i>European Neuropsychopharmacology</i> , 2022, 60, 91-99.	0.3	9
6	Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2021, , 1-9.	2.7	1
7	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. <i>Bipolar Disorders</i> , 2021, 23, 659-678.	1.1	27
8	The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. <i>JMIR Research Protocols</i> , 2021, 10, e31439.	0.5	5
9	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021, 23, 767-788.	1.1	32
10	Call to action regarding the vascularâ€bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. <i>Bipolar Disorders</i> , 2020, 22, 440-460.	1.1	66
11	Serum epidermal growth factor, clinical illness course, and limbic brain volumes in early-stage bipolar disorder. <i>Journal of Affective Disorders</i> , 2020, 270, 30-35.	2.0	5
12	Association of Cytomegalovirus and <i>Toxoplasma gondii</i> Antibody Titers With Bipolar Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 1285.	6.0	36
13	Genetic variant in SLC1A2 is associated with elevated anterior cingulate cortex glutamate and lifetime history of rapid cycling. <i>Translational Psychiatry</i> , 2019, 9, 149.	2.4	19
14	Mood Stabilisers in the Treatment of Bipolar II Disorder. , 2019, , 129-142.		0
15	Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective <i>sc</i> MRI <i>sc</i> study. <i>Bipolar Disorders</i> , 2019, 21, 50-60.	1.1	23
16	Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder. <i>Journal of Affective Disorders</i> , 2019, 245, 679-685.	2.0	31
17	Investigating the complex relationship between bipolarity and obesity: â€Not because it is easy, but because it is hardâ€. <i>Bipolar Disorders</i> , 2019, 21, 106-107.	1.1	0
18	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 108-113.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.1	1,079
20	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	1.3	18
21	Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. <i>Translational Psychiatry</i> , 2018, 8, 188.	2.4	44
22	Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 65-74.	1.3	9
23	Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 210, 403-407.	1.7	50
24	Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. <i>Translational Psychiatry</i> , 2017, 7, e1071-e1071.	2.4	13
25	Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 239-249.	2.2	20
26	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. <i>Journal of Psychiatric Research</i> , 2017, 95, 208-212.	1.5	4
27	Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2017, 208, 291-297.	2.0	20
28	Assessment of Proteomic Measures Across Serious Psychiatric Illness. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, 11, 103-112.	1.4	3
29	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 441-448.	1.1	18
30	Mania secondary to focal brain lesions: implications for understanding the functional neuroanatomy of bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 205-220.	1.1	61
31	Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. <i>Bipolar Disorders</i> , 2016, 18, 511-519.	1.1	64
32	Clinical features of bipolar spectrum with binge eating behaviour. <i>Journal of Affective Disorders</i> , 2016, 201, 95-98.	2.0	29
33	Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2016, 65, 76-83.	1.3	37
34	Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016, 208, 146-152.	1.7	16
35	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 191, 216-221.	2.0	62
36	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. <i>Molecular Psychiatry</i> , 2016, 21, 1050-1056.	4.1	42

#	ARTICLE	IF	CITATIONS
37	A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. <i>Psychological Medicine</i> , 2015, 45, 693-704.	2.7	311
38	A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability. <i>Journal of Psychiatric Research</i> , 2015, 62, 23-30.	1.5	93
39	A Multidisciplinary First-Episode Psychosis Program. <i>Psychiatric Annals</i> , 2015, 45, 561-568.	0.1	0
40	<sup>13</sup> C Magnetic Resonance Spectroscopy and Glutamate Metabolism in Mood Disorders: Current Challenges, Potential Opportunities. <i>American Journal of Psychiatry</i> , 2014, 171, 1240-1242.	4.0	7
41	Childhood maltreatment and corpus callosum volume in recently diagnosed patients with bipolar I disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Psychiatric Research</i> , 2014, 48, 65-72.	1.5	17
42	12-month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 159-171.	1.1	49
43	Comprehensive Pharmacologic Management of Bipolar Depression. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 263-277.	0.7	0
44	Body Mass Index-Related Regional Gray and White Matter Volume Reductions in First-Episode Mania Patients. <i>Biological Psychiatry</i> , 2014, 76, 138-145.	0.7	48
45	Neurocognitive Functioning in Overweight and Obese Patients with Bipolar Disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Canadian Journal of Psychiatry</i> , 2014, 59, 639-648.	0.9	18
46	Cognitive Change in the Year After a First Manic Episode. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e587-e593.	1.1	45
47	The impact of childhood trauma on cognitive functioning in patients recently recovered from a first manic episode: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).. <i>Journal of Affective Disorders</i> , 2013, 148, 424-430.	2.0	31
48	Relationship between frontostriatal morphology and executive function deficits in bipolar I disorder following a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Bipolar Disorders</i> , 2013, 15, 657-668.	1.1	22
49	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	4.0	579
50	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	1.1	740
51	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. <i>Bipolar Disorders</i> , 2013, 15, 58-60.	1.1	14
52	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. <i>Bipolar Disorders</i> , 2013, 15, 338-339.	1.1	1
53	The relationship between clinical outcomes and quality of life in first-episode mania: a longitudinal analysis. <i>Bipolar Disorders</i> , 2013, 15, 188-198.	1.1	25
54	Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials. <i>Journal of Affective Disorders</i> , 2013, 150, 408-414.	2.0	46

#	ARTICLE	IF	CITATIONS
55	Systematic review of neurocognition and occupational functioning in major depressive disorder. <i>Neuropsychiatry</i> , 2013, 3, 97-105.	0.4	36
56	Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. <i>International Clinical Psychopharmacology</i> , 2012, 27, 91-99.	0.9	22
57	Which Depressive Symptoms and Medication Side Effects Are Perceived by Patients as Interfering Most with Occupational Functioning?. <i>Depression Research and Treatment</i> , 2012, 2012, 1-6.	0.7	50
58	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. <i>Bipolar Disorders</i> , 2012, 14, 478-487.	1.1	184
59	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 23-37.	0.6	74
60	The Association of Elevated Body Mass Index with Reduced Brain Volumes in First-Episode Mania. <i>Biological Psychiatry</i> , 2011, 70, 381-387.	0.7	62
61	Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features. <i>International Clinical Psychopharmacology</i> , 2011, 26, 146-150.	0.9	10
62	Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. <i>Psychological Medicine</i> , 2011, 41, 971-982.	2.7	73
63	Neurocognitive Functioning in Patients With Bipolar I Disorder Recently Recovered From a First Manic Episode. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1234-1242.	1.1	134
64	Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2010, 124, 108-117.	2.0	29
65	Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2010, 124, 228-234.	2.0	106
66	The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Bipolar Disorders</i> , 2010, 12, 616-626.	1.1	31
67	Marcadores de estrés oxidativo en el trastorno bipolar: un metaanálisis. <i>Psiquiatria Biologica</i> , 2009, 16, 60-69.	0.0	0
68	Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. <i>Comprehensive Psychiatry</i> , 2009, 50, 1-8.	1.5	55
69	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 447.	1.0	343
70	Course and Outcome after the First Manic Episode in Patients with Bipolar Disorder: Prospective 12-Month Data from the Systematic Treatment Optimization Program for Early Mania Project. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 105-112.	0.9	85
71	3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 263-71.	1.4	140
72	Oxidative stress markers in bipolar disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2008, 111, 135-144.	2.0	442

#	ARTICLE	IF	CITATIONS
73	Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. <i>International Clinical Psychopharmacology</i> , 2008, 23, 88-94.	0.9	32
74	Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1589-1601.	1.1	113
75	Forum "Melancholia. <i>Current Opinion in Psychiatry</i> , 2007, 20, 203-205.	3.1	0
76	Forum "Melancholia. <i>Current Opinion in Psychiatry</i> , 2007, 20, 202-203.	3.1	1
77	Oxcarbazepine in the Treatment of Bipolar Disorder: A Review. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 540-545.	0.9	28
78	A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. <i>Schizophrenia Research</i> , 2001, 52, 37-46.	1.1	135
79	Bipolar II disorder in context: a review of epidemiology, disability and economic burden. , 0, , 46-55.		1
80	Current status of mood stabilisers in the management of Bipolar II disorder. , 0, , 114-125.		0